Real-world examples of cannabis-based medicinal products (CBMPs) being successfully integrated into NHS treatment pathways, highlighting patient outcomes, prescribing trends, and collaboration between specialist clinics and NHS services.

Presentation of new clinical trial outcomes from UK clinics focused on OCD and anxiety, offering insight into the effectiveness of CBMPs in managing complex mental health conditions, and what this could mean for broader adoption.

A deep dive into best practices for pharmacists involved in dispensing CBMPs, including safety checks, patient counselling procedures, and monitoring strategies to ensure safe and compliant supply within regulated environments.

Exploration of the evolving frameworks for CBMP prescribers, including training requirements, clinical governance standards, and data-driven monitoring tools that support evidence-based, accountable prescribing.

An overview of promising areas of CBMP use beyond chronic pain, such as in dementia care, neurological pain management, and as supportive therapy in oncology – backed by emerging data and case study insights.

Discussion of how the sector is preparing to scale access to as many as 500,000 patients across the UK, while maintaining high standards of clinical safety, regulatory oversight, and equitable access for diverse populations.